Literature DB >> 6280890

Hemodynamic and radionuclide effects of acute captopril therapy for heart failure: changes in left and right ventricular volumes and function at rest and during exercise.

B Massie, B L Kramer, N Topic, S G Henderson.   

Abstract

Although the resting hemodynamic effects of captopril in congestive heart failure are known, little information is available about the hemodynamic response to captopril during exercise or about changes in noninvasive measurements of the size and function of both ventricles. In this study, 14 stable New York Heart Association class III patients were given 25 mg or oral captopril. Rest and exercise hemodynamic measurements and blood pool scintigrams were performed simultaneously before and 90 minutes after captopril. The radionuclide studies were analyzed for left and right ventricular end-diastolic volumes, end-systolic volumes, ejection fractions and pulmonary blood volume. The primary beneficial responses at rest were decreases in left and right ventricular end-diastolic volumes from 388 +/- 81 to 350 +/- 77 ml (p less than 0.01) and from 52 +/- 26 to 43 +/- 20 volume units (p less than 0.01), respectively, and in their corresponding filling pressures, from 24 +/- 10 to 17 +/- 9 mm Hg and 10 +/- 5 to 6 +/- 5 mm Hg (both p less than 0.001). Although stroke volume did not increase significantly, both left and right ventricular ejection fractions increased slightly, from 19 +/- 6% to 22 +/- 5% and from 25 +/- 9% to 29 +/- 11%, respectively (both p less than 0.01). During exercise, similar changes were noted in both hemodynamic and radionuclide indexes. Thus, in patients with moderate symptomatic limitation from chronic heart failure, captopril predominantly reduces ventricular volume and filling pressure, with a less significant effect on cardiac output. These effects persist during exercise, when systemic vascular resistance is already very low. Radionuclide techniques are valuable in assessing the drug effect in these subjects, particularly when ventricular volumes are also measured.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280890     DOI: 10.1161/01.cir.65.7.1374

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  Novel Insights and Treatment Strategies for Right Heart Failure.

Authors:  Weiqin Lin; Ai-Ling Poh; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2018-06

Review 2.  Do we have two hearts? New insights in right ventricular function supported by myocardial imaging echocardiography.

Authors:  Antonio Vitarelli; Claudio Terzano
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

3.  Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects.

Authors:  H Stern; J Weil; T Genz; W Vogt; K Bühlmeyer
Journal:  Pediatr Cardiol       Date:  1990-01       Impact factor: 1.655

Review 4.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 5.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

6.  Isometric exercise for the evaluation of vasodilatory therapy in severe congestive heart failure.

Authors:  F F Hertrich; B R Winkelmann; H Leinberger
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

7.  Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure.

Authors:  Philippe Meyer; Gerasimos S Filippatos; Mustafa I Ahmed; Ami E Iskandrian; Vera Bittner; Gilbert J Perry; Michel White; Inmaculada B Aban; Marjan Mujib; Louis J Dell'Italia; Ali Ahmed
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

Review 8.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

Review 9.  The use of angiotensin-converting enzyme inhibitors in congestive heart failure.

Authors:  J L Rouleau; C Juneau; J de Champlain
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

10.  Right ventricular failure in congenital heart disease.

Authors:  Young Kuk Cho; Jae Sook Ma
Journal:  Korean J Pediatr       Date:  2013-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.